In particular, human clinical studies of MUC1 conjugated to the carrier mannan has been in phase I, II, III trials, and in early stage breast cancer patients these conjugates show protection against recurrence up to 18 years post-vaccination clinical follow-up [47,48,49,50]. The gene discussed is MUC1; the disease is breast carcinoma.